Document is current
Any future updates will be listed below
-
Authors
Agarwal, Rajni
Bertaina, Alice
Soco, Charmaine https://orcid.org/0000-0002-3853-7052
Long-Boyle, Janel R.
Saini, Gopin
Kunte, Nivedita
Hiroshima, Lyndsie
Chan, Yan Y.
Willner, Hana
Krampf, Mark R.
Nofal, Rofida
Barbarito, Giulia
Sen, Sushmita
Van Hentenryck, Maite https://orcid.org/0000-0002-5188-9298
Walck, Emily
Scheck, Amelia
Perriman, Rhonda J.
Bouge, Alisha
Istomina, Elena
Din, Hena Naz
Klinger, Edna F.
Cheng, Jerry C.
Wlodarski, Marcin W. https://orcid.org/0000-0001-6638-9643
Boelens, Jaap J.
Shizuru, Judith A. https://orcid.org/0000-0003-3246-4726
Pang, Wendy W.
Weinberg, Kenneth
Parkman, Robertson
Roncarolo, Maria Grazia https://orcid.org/0000-0003-1636-1495
Porteus, Matthew https://orcid.org/0000-0002-3850-4648
Czechowicz, Agnieszka https://orcid.org/0000-0003-2909-2669
-
Funding
Funding for this research was provided by:
California Institute for Regenerative Medicine (CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315, CLIN2-14315)
Anonymous Philanthropic Funding
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 3 June 2025
First Online: 22 July 2025
Competing interests
: A.B. is a consultant and received honoraria from Miltenyi and Neovii. L.H. is a member of an advisory committee of and received honoraria from Sobi. J.J.B. received honoraria from Advanced Clinical and is a consultant for and received honoraria from Immusoft, Sanofi, Sobi and SmartImmune. J.A.S. and W.W.P. are consultants and current equity holders for Jasper Therapeutics. M.G.R. is a current equity holder for Graphite Biologics, TR1X, Atara and Kamau Therapeutics and a member of their boards of directors or advisory committees. M.P. is a current equity holder for Graphite Biologics, Allogene Therapeutics and Alaunos Therapeutics and a member of their boards of directors or advisory committees; he is also a current equity holder of Kamau Therapeutics and CRISPR Tx. A.C. is a current equity holder of Beam Therapeutics, Dianthus Therapeutics and Editas Medicines; a consultant and/or current equity holder for Fulcrum Therapeutics, GV, Land Medicine and Kyowa Kirin; holds patents and royalties for Inograft Biotherapeutics and is a current equity holder and member of their advisory committee; holds patents and royalties for and research funding from Jasper Therapeutics; holds patents and royalties for Magenta Therapeutics; is a current equity holder for and a member of advisory committees for Permanence Bio and Prime Medicines; has research funding from and is a consultant for Rocket Pharma; and is a current equity holder for Spotlight Therapeutics and Teiko Bio. In addition, A.C. and other authors are inventors on various patents related to antibody-based conditioning. The remaining authors declare no competing interests.
